Triamcinolone acetonide decreases outflow facility in C57BL/6 mouse eyes

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 2, 2013, Pages 1280-1287

  Kumar, Sandeep ^a   Shah, Shaily ^b,c   Deutsch, Emily Rose ^a   Tang, Hai Michael ^a   Danias, John ^a,b  

^a SUNY Downstate Medical Center   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; MYOCILIN; TRIAMCINOLONE ACETONIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR OUTFLOW; ARTICLE; CONTROLLED STUDY; FEMALE; INTRAOCULAR PRESSURE; MOUSE; NONHUMAN; OCULOPLETHYSMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SPECTROPHOTOMETRY;

ANIMALS; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; EYE PROTEINS; FEMALE; GLAUCOMA; GLUCOCORTICOIDS; GLYCOPROTEINS; HYDROCORTISONE; INTRAOCULAR PRESSURE; MICE; MICE, INBRED C57BL; MICRODIALYSIS; MODELS, BIOLOGICAL; RNA, MESSENGER; TRABECULAR MESHWORK; TRIAMCINOLONE ACETONIDE;

EID: 84874951883     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11223     Document Type: Article

References (45)

1. Jones R III, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17:163-167.
2. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond). 2006;20:407-416.
3. Becker B, Mills DW. Corticosteroids and intraocular pressure. Arch Ophthalmol. 1963;70:500-507.
4. Goldmann H. Cortisone glaucoma. Arch Ophthalmol. 1962; 68:621-626.
5. Bernstein HN, Schwartz B. Effects of long-term systemic steroids on ocular pressure and topographic values. Arch Ophthalmol. 1962;68:742-753.
6. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70:482-491.
7. Rohen JW, Linner E, Witmer R. Electron microscopic studies on the trabecular meshwork in two cases of corticosteroidglaucoma. Exp Eye Res. 1973;17:19-31.
8. Roll P, Benedikt O. Electronmicroscopic studies of the trabecular meshwork in corticosteroid glaucoma [in German]. Klin Monbl Augenheilkd. 1979;174:421-428.
9. Johnson D, Gottanka J, Flugel C, Hoffmann F, Futa R, Lutjen-Drecoll E. Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids. Arch Ophthalmol. 1997;115:375-383.
10. Zhang X, Clark AF, Yorio T. Regulation of glucocorticoid responsiveness in glaucomatous trabecular meshwork cells by glucocorticoid receptor-beta. Invest Ophthalmol Vis Sci. 2005;46:4607-4616.
11. Clark AF, Wilson K, McCartney MD, Miggans ST, Kunkle M, Howe W. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1994;35:281-294.
12. Wilson K, McCartney MD, Miggans ST, Clark AF. Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells. Curr Eye Res. 1993;12:783-793.
13. Yue BY. The extracellular matrix and its modulation in the trabecular meshwork. Surv Ophthalmol. 1996;40:379-390.
14. Johnson DH, Bradley JM, Acott TS. The effect of dexamethasone on glycosaminoglycans of human trabecular meshwork in perfusion organ culture. Invest Ophthalmol Vis Sci. 1990; 31:2568-2571.
15. Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog Retin Eye Res. 1999;18:629-667.
16. Snyder RW, Stamer WD, Kramer TR, Seftor RE. Corticosteroid treatment and trabecular meshwork proteases in cell and organ culture supernatants. Exp Eye Res. 1993;57:461-468.
17. Shirato S, Bloom E, Polansky J, Alvarado J, Stilwell L. Phagocytic properties of confluent human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1988;29:S125.
18. Bhattacherjee P, Paterson CA, Spellman JM, Graff G, Yanni JM. Pharmacological validation of a feline model of steroidinduced ocular hypertension. Arch Ophthalmol. 1999;117: 361-364.
19. Fingert JH, Clark AF, Craig JE, et al. Evaluation of the myocilin (MYOC) glaucoma gene in monkey and human steroidinduced ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42:145-152.
20. Knepper PA, Breen M, Weinstein HG, Blacik JL. Intraocular pressure and glycosaminoglycan distribution in the rabbit eye: effect of age and dexamethasone. Exp Eye Res. 1978;27:567-575.
21. Lorenzetti OJ. Effects of corticosteroids on ocular dynamics in rabbits. J Pharmacol Exp Ther. 1970;175:763-772.
22. Sawaguchi K, Nakamura Y, Sakai H, Sawaguchi S. Myocilin gene expression in the trabecular meshwork of rats in a steroid-induced ocular hypertension model. Ophthalmic Res. 2005;37:235-242.
23. Zhan GL, Miranda OC, Bito LZ. Steroid glaucoma: corticosteroid-induced ocular hypertension in cats. Exp Eye Res. 1992; 54:211-218.
24. Gerometta R, Podos SM, Candia OA, et al. Steroid-induced ocular hypertension in normal cattle. Arch Ophthalmol. 2004; 122:1492-1497.
25. Gerometta R, Podos SM, Danias J, Candia OA. Steroid-induced ocular hypertension in normal sheep. Invest Ophthalmol Vis Sci. 2009;50:669-673.
26. Whitlock NA, McKnight B, Corcoran KN, Rodriguez LA, Rice DS. Increased intraocular pressure in mice treated with dexamethasone. Invest Ophthalmol Vis Sci. 2010;51:6496-6503.
27. Aihara M, Lindsey JD, Weinreb RN. Aqueous humor dynamics in mice. Invest Ophthalmol Vis Sci. 2003;44:5168-5173.
28. Danias J, Kontiola AI, Filippopoulos T, Mittag T. Method for the noninvasive measurement of intraocular pressure in mice. Invest Ophthalmol Vis Sci. 2003;44:1138-1141.
29. Nissirios N, Goldblum D, Rohrer K, Mittag T, Danias J. Noninvasive determination of intraocular pressure (IOP) in nonsedated mice of 5 different inbred strains. J Glaucoma. 2007;16:57-61.
30. Millar JC, Clark AF, Pang IH. Assessment of aqueous humor dynamics in the mouse by a novel method of constant-flow infusion. Invest Ophthalmol Vis Sci. 2011;52:685-694.
31. Bollinger K, Kim J, Lowder CY, Kaiser PK, Smith SD. Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis. Ophthalmology. 2011;118:1927-1931.
32. Clark AF. Basic sciences in clinical glaucoma: steroids, ocular hypertension, and glaucoma. J Glaucoma. 1995;4:354-369.
33. Lam DS, Fan DS, Ng JS, Yu CB, Wong CY, Cheung AY. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin Experiment Ophthalmol. 2005;33:252-258.
34. Clark AF. Mechanism of action of the angiostatic cortisene anecortave acetate. Surv Ophthalmol. 2007;52:S26-S34.
35. McNatt LG, Weimer L, Yanni J, Clark AF. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther. 1999;15:413-423.
36. Robin AL, Suan EP, Sjaarda RN, Callanan DG, Defaller J. Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection-related glaucoma. Arch Ophthalmol. 2009;127:173-178.
37. Robin AL, Clark AF, Covert DW, et al. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation. Am J Ophthalmol. 2009;147: 45-50. e2.
38. Candia OA, Gerometta R, Millar JC, Podos SM. Suppression of corticosteroid-induced ocular hypertension in sheep by anecortave. Arch Ophthalmol. 2010;128:338-343.
39. Stalmans I, Callanan DG, Dirks MS, et al. Treatment of steroidinduced elevated intraocular pressure with anecortave acetate: a randomized clinical trial. J Ocul Pharmacol Ther. 2012; 28:559-565.
40. Clark AF, Steely HT, Dickerson JE Jr, et al. Glucocorticoid induction of the glaucoma gene MYOC in human and monkey trabecular meshwork cells and tissues. Invest Ophthalmol Vis Sci. 2001;42:1769-1780.
41. Kim BS, Savinova OV, Reedy MV, et al. Targeted disruption of the myocilin gene (Myoc) suggests that human glaucomacausing mutations are gain of function. Mol Cell Biol. 2001;21: 7707-7713.
42. Gould DB, Miceli-Libby L, Savinova OV, et al. Genetically increasing Myoc expression supports a necessary pathologic role of abnormal proteins in glaucoma. Mol Cell Biol. 2004;24: 9019-9025.
43. McDowell CM, Luan T, Zhang Z, et al. Mutant human myocilin induces strain specific differences in ocular hypertension and optic nerve damage in mice. Exp Eye Res. 2012;100:65-72.
44. Shepard AR, Jacobson N, Millar JC, et al. Glaucoma-causing myocilin mutants require the Peroxisomal targeting signal-1 receptor (PTS1R) to elevate intraocular pressure. Hum Mol Genet. 2007;16:609-617.
45. Robin AL, Weiner AL, Marsh DA, inventors; Alcon, Inc., assignee. Method for treating primary and secondary forms of glaucoma. US patent US2007/0197491 A1. August 23, 2007.